Olivia Vizier

If data is the new oil, CytoReason is one of its barons. Combining all available information about a disease – literature, data sets, all data types – the company builds computational disease models utilized by its pharma partners to help them determine which drug avenues to pursue next.

Elicio is merging with Angion Biomedica, a Uniondale, NY-based biotech that began searching for strategic alternatives last July after Phase II setbacks forced it to shutter all R&D work.

In 2021, PepGen raised $113 million to challenge Sarepta in DMD and build its neuromuscular and neurologic pipeline.

AbbVie has tapped Immunome’s discovery platform in a heavily backended partnership and option agreement in a bid to discover 10 antibody-target pairs from three as-yet-unnamed tumor types.

French-American biotech Amolyt Pharma has raised a €130 million ($138 million) Series C round, planning to use the cash to take its hypoparathyroidism drug into final-stage testing and move another experimental drug into the clinic.

Brian Wiley, chief business officer at Portage Biotech, spoke of striking a balance between in-person and virtual meetings.

Biotech company F2G announced today the FDA has accepted its NDA filing for its antifungal therapy, Olorofim. The FDA has set the Prescription Drug User Fee Act (PDUFA) date for June 17, 2023.

Seattle-based biotech EMulate Therapeutics is working hard on the latter, developing technology that leverages magnetic fields to emulate the information inherent to therapeutic molecules and replicate their therapeutic effects without ever administering the molecules to patients.

Drug developers are designing new psychedelic compounds to treat depression and other mental-health conditions but skip the trip.

While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that, measured in addressable patient market terms, is considerably bigger.

With pipeline and patent expiration pressures, large pharmaceutical companies will need to strategically acquire or align with biotechnology companies providing potential solutions to core asset life cycle management, as well as accessing proprietary assets to address pipeline gaps.

On Monday, Elixirgen Therapeutics and its research collaborators will present data from the company’s lead candidate, EXG-34217, a first-in-human cell therapy that aims to extend telomere length in patients with telomere biology disorders.

While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that, measured in addressable patient market terms, is considerably bigger.

Theseus’ pan-variant inhibitor candidates are designed to outsmart cancer treatment resistance by precluding that “arms race.” Pan-variant inhibitors are single therapeutic agents that maintain their anti-cancer activity against a target protein in the face of any and all major classes of cancer-causing and resistance mutations.

PepGen was one of a handful of biotech companies to go public this year, tapping into capital markets despite high inflation and economic conditions that have leading analysts predicting a global recession throughout 2023.

The concept behind EMulate’s approach is mind-boggling. The company “records” the electromagnetic signature of specific molecules and is then able to use those recordings to effect changes in cellular behaviour, without using chemicals. In its most advanced programme, EMulate’s technology has completed feasibility clinical trials for adults and children with terminal brain cancer, using a

When Dr. Philip Toleikis joined Sernova in 2009, the company’s technology appeared as more of a concept than anything else. But, he saw the potential for something groundbreaking:

“The Portage model has the same goal, which is to get to human proof-of-concept as quickly as possible,” says Walters. “

“We’re in a steel mill town,” Keir Loiacono, chief executive officer at BlueSphere Bio told BioSpace. “I can look from my office out of the glass buildings and see coal barges going through, right next to young scientists in lab coats. It’s the old and the new – it’s everybody working together.”

An anti-CD70 antibody-drug conjugate developed by Ambrx, Inc. has been administered to the first patient in a Phase I study in China. It marks the first ADC in active development that targets CD70, according to the company.

In this video from ASN Kidney Week, Jonathan Barratt, MBChB, PhD, discusses Calliditas Therapeutics’ Tarpeyo treatment, previously known as Nefecon, for patients with IgA nephropathy.

TFF Pharmaceuticals is advancing this technique as a platform technology for improving the formulation of complex modalities, including vaccines, small molecules and biologics, as dry powders. According to Hannon, this approach provides key advantages, including access to more convenient routes of administration due to aerosolization properties (i.e., inhalation or intranasal delivery) and elimination of the

The Thin Film Freezing technology, invented by Dr. Williams and his team and advanced by Fort Worth-based TFF Pharmaceuticals, is developed via a well controlled process that involves rapid freezing and drying drugs into a powder.

MIT-born startup Elicio Therapeutics’ novel Amphiphile Technology Platform is designed to directly engage the lymphatic system in the deployment and delivery of therapeutic payloads.

Fungal infections kill more than 1.6 million people yearly, according to Global Action for Fungal Infections, a research and fundraising organization. The toll is climbing. Fungi are adapting to rising temperatures in ways that may make them better suited to thrive in the human body, researchers said. And more people undergoing treatments that weaken their

Ring Therapeutics, have revealed 60 open reading frame 1 (ORF1) protein fragments that feature a modified jelly-roll–domain core architecture, with residues that extend from the surface to

One such method is based on ImmTOR nanoparticles (Selecta Biosciences), which leverage rapamycin to generate antigen-specific immune tolerance (Figure 1). The nanoparticles are designed to accumulate in the spleen and liver

Dr. Diem Nguyen,  the CEO of Xalud Therapeutics, talks about Xalud’s work to reduce the inflammation that drives pain. It’s now in human clinical trials.

SOTIO, for example – an international biotech originating from the Czech Republic – focuses on immuno-oncology and developing innovative methods for treating cancer. The company has been conducting multiple Phase I to III clinical trials, and uniquely uses four distinct technological platforms, which each include multiple promising drug candidates.

Yochi Slonim, M.Sc., co-founder and CEO of Anima Biotech, explained the rationale for building a platform technology company in Israel.